USPTO to Issue MDRNA Patent on siRNAs Targeting JAM-1 Gene | GenomeWeb

MDRNA announced this week that the US Patent and Trademark Office intends to issue the company a patent covering an siRNA directed against the junctional adhesion molecule-1 gene.

"JAM-1 is a tight junction protein that plays a key role in maintaining epithelial and endothelial barrier functions, leukocyte transmigration, and platelet adhesion, and also functions as a pro-inflammatory molecule," the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.